Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pertussis filamentous haemagglutinin
- Development stage
- Approved
- Lead developer
- University of Antwerp
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pertussis filamentous haemagglutinin (FHA) is a large, 220 kDa cell-surface protein produced by *Bordetella pertussis* that serves as a critical adhesin for bacterial colonization of the respiratory tract. It mediates attachment to ciliated respiratory epithelial cells and leukocytes by binding to various host cell receptors, including galactose-containing glycoconjugates and the CR3 integrin (CD11b/CD18). As a key component of acellular pertussis (aP) vaccines, FHA is used to induce a protective immune response, primarily through the production of neutralizing antibodies that inhibit bacterial adherence and promote opsonization. The University of Antwerp has been a prominent site for the clinical development and evaluation of FHA-containing vaccines, including their use in multi-valent combinations with diphtheria and tetanus toxoids for the prevention of pertussis in infants, adolescents, and adults.
- Brand names
- AdacelBoostrixDaptacelHexacimaInfanrixInfanrix HexaKinrixPediarixPentacelQuadracelVaxelis
- Other names
- filamentous hemagglutininfilamentous haemagglutinin
02
Targets
TLR2 (Toll-like Receptor 2)sGAGs (Sulfated glycosaminoglycans/heparin)
Beyond the preview
Go deeper on pertussis filamentous haemagglutinin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pertussis filamentous haemagglutinin.